GCK Antibody (G-5): sc-55496
- GCK Antibody (G-5) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against amino acids 318-405 mapping near the C-terminus of GCK of human origin
- recommended for detection of GCK of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for GCK Antibody (G-5) for WB applications. These reagents are now offered in bundles with GCK Antibody (G-5) (see ordering information below).
QUICK LINKS
SEE ALSO...
GCK Antibody (G-5) is a mouse monoclonal IgG1 antibody that detects glucokinase (GCK) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GCK plays a crucial role in glucose metabolism, primarily functioning as a glucose sensor in pancreatic beta cells, where GCK regulates insulin secretion in response to glucose levels. This regulation is vital for maintaining glucose homeostasis in the body, as GCK determines the threshold for insulin release, thereby influencing blood sugar levels. Additionally, GCK is also expressed in the liver, where GCK catalyzes the phosphorylation of glucose, marking the first committed step in glucose disposal. The activity of GCK is essential; any deficiency can lead to impaired insulin secretion and hyperglycemia, conditions that are often associated with maturity onset diabetes of the youth (MODY). Notably, mutations in the GCK gene have been linked to this form of diabetes, highlighting GCK′s significance in metabolic health. Anti-GCK antibody (G-5) is an invaluable tool for researchers studying glucose metabolism and its implications in diabetes and other metabolic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GCK Antibody (G-5) References:
- The GCK II and III subfamilies of the STE20 group kinases. | Pombo, CM., et al. 2007. Front Biosci. 12: 850-9. PMID: 17127342
- Evaluation of pregnancy outcomes in women with GCK-MODY. | López Tinoco, C., et al. 2021. Diabet Med. 38: e14488. PMID: 33277730
- Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY. | Wang, X., et al. 2021. Redox Biol. 40: 101855. PMID: 33450726
- Variable presentations of GCK gene mutation in a family. | Oza, CM., et al. 2022. BMJ Case Rep. 15: PMID: 35228227
- Mutations in GCK May Lead to MODY2 by Reducing Glycogen Synthesis. | Li, Z., et al. 2022. Adv Biol (Weinh). 6: e2200097. PMID: 35770790
- Maternal and Infant Outcomes in GCK-MODY Complicated by Pregnancy. | Ren, Q., et al. 2023. J Clin Endocrinol Metab. 108: 2739-2746. PMID: 37011183
- GCK exonic mutations induce abnormal biochemical activities and result in GCK-MODY. | Dai, T., et al. 2023. Front Genet. 14: 1120153. PMID: 37082200
- Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis. | Liu, J., et al. 2023. J Diabetes. 15: 519-531. PMID: 37226652
- Partial GCK gene deletion mutations causing maturity-onset diabetes of the young. | Yu, R., et al. 2024. Acta Diabetol. 61: 107-115. PMID: 37704826
- Integration of proteomics and metabolomics reveals energy and metabolic alterations induced by glucokinase (GCK) partial inactivation in hepatocytes. | Xie, Z., et al. 2024. Cell Signal. 114: 111009. PMID: 38092300
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCK Antibody (G-5) | sc-55496 | 200 µg/ml | $322.00 | |||
GCK Antibody (G-5): m-IgG Fc BP-HRP Bundle | sc-539021 | 200 µg Ab; 10 µg BP | $361.00 | |||
GCK Antibody (G-5): m-IgG1 BP-HRP Bundle | sc-541212 | 200 µg Ab; 20 µg BP | $361.00 |